and the European APL 91 GroupWe designed a multicenter randomized trial comparing chemotherapy with daunorubicin-Ara C (chemotherapy group) and all transretinoic acid (ATRA) combined to the same chemotherapy (ATRA group) in newly diagnosed APL patients aged 65 years or less. The major endpoint of the study was event-free survival (EFS) ("events" being defined as failure to achieve complete remission [CR], occurrence of relapse, or death in CR). Early termination of the trial was decided after the first interim analysis, as EFS was significantly higher in the ATRA group. At the time, 101 patients had been randomized (54 in the ATRA group and 47 in the chemotherapy group). In the ATRA group, 49 (91 %) patients achieved CR, 5 (9%) had early death, and 0 had resistant leukemia, compared with 38 (81 %), 4 (8%). and 5 (10%) patients, respectively, in the chemotherapy
CUTE PROMYELOCYTIC leukemia (APL) is charac-A terized by the morphology of blast cells (M3),'s2 by From the European APL 91 Group (members listed in Appendix).